IONS Ionis Pharmaceuticals, Inc. Stock Quote

IONS [NASD]

Index	-	P/E	-	EPS (ttm)	-0.03	Insider Own	0.30%	Shs Outstand	141.60M	Perf Week	-4.71%
Market Cap	5.20B	Forward P/E	-	EPS next Y	-2.80	Insider Trans	-1.78%	Shs Float	140.69M	Perf Month	-4.85%
Income	-3.90M	PEG	-	EPS next Q	-0.61	Inst Own	89.60%	Short Float	5.07%	Perf Quarter	12.73%
Sales	840.80M	P/S	6.18	EPS this Y	93.60%	Inst Trans	1.62%	Short Ratio	6.56	Perf Half Y	29.54%
Book/sh	5.01	P/B	7.51	EPS next Y	-13.20%	ROA	-0.20%	Target Price	47.28	Perf Year	1.02%
Cash/sh	14.86	P/C	2.53	EPS next 5Y	-	ROE	-0.60%	52W Range	25.04 - 44.42	Perf YTD	23.66%
Dividend	-	P/FCF	127.07	EPS past 5Y	16.50%	ROI	-1.90%	52W High	-15.29%	Beta	0.76
Dividend %	-	Quick Ratio	9.80	Sales past 5Y	16.80%	Gross Margin	98.50%	52W Low	50.28%	ATR	1.88
Employees	660	Current Ratio	9.90	Sales Q/Q	27.20%	Oper. Margin	-0.50%	RSI (14)	50.03	Volatility	4.32% 5.21%
Optionable	Yes	Debt/Eq	1.76	EPS Q/Q	27.90%	Profit Margin	-0.50%	Rel Volume	1.49	Prev Close	36.65
Shortable	Yes	LT Debt/Eq	1.76	Earnings	May 04 BMO	Payout	-	Avg Volume	1.09M	Price	37.63
Recom	2.70	SMA20	1.69%	SMA50	-1.09%	SMA200	9.58%	Volume	1,617,231	Change	2.67%

Mar-31-22

Resumed

Piper Sandler

Overweight

$54

Mar-01-22

Initiated

Guggenheim

Buy

$64

Mar-01-22

Initiated

Citigroup

Sell

$26

Feb-01-22

Downgrade

BofA Securities

Buy → Underperform

$40 → $30

Dec-14-21

Upgrade

William Blair

Mkt Perform → Outperform

May-07-21

Upgrade

UBS

Sell → Neutral

$33 → $37.50

Mar-01-21

Upgrade

Barclays

Underweight → Equal Weight

$50 → $52

Dec-16-20

Initiated

UBS

Sell

$34

Dec-15-20

Upgrade

Cowen

Market Perform → Outperform

Sep-14-20

Resumed

JP Morgan

Neutral

$63

Sep-02-20

Initiated

The Benchmark Company

Hold

Jun-01-20

Resumed

Oppenheimer

Outperform

May-13-20

Initiated

RBC Capital Mkts

Outperform

$71

Mar-05-20

Initiated

Citigroup

Buy

$73

Dec-13-19

Initiated

Oppenheimer

Outperform

Nov-13-19

Initiated

BofA/Merrill

Buy

$70

Nov-07-19

Downgrade

Morgan Stanley

Equal-Weight → Underweight

$63 → $48

Sep-10-19

Upgrade

Bernstein

Mkt Perform → Outperform

Aug-08-18

Reiterated

Stifel

Hold

$48 → $47

Aug-07-18

Reiterated

Stifel

Hold

$55 → $48

May-12-22 07:05AM	Ionis to present at RBC Capital Markets Global Healthcare Conference PR Newswire +6.33%
May-06-22 07:23AM	We Think Ionis Pharmaceuticals (NASDAQ:IONS) Can Stay On Top Of Its Debt Simply Wall St.
May-05-22 11:45AM	Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises Zacks
May-04-22 08:15AM	Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	Ionis reports first quarter financial results and recent business achievements PR Newswire
May-02-22 07:05AM	Ionis to host 2022 virtual Annual Meeting of Stockholders PR Newswire
Apr-27-22 03:03PM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Apr-20-22 07:05AM	Ionis to hold first quarter 2022 financial results webcast PR Newswire
Apr-04-22 12:15AM	Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session PR Newswire
Mar-29-22 01:03PM	Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development Zacks
Mar-28-22 07:30AM	Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis GlobeNewswire
Mar-21-22 07:05AM	Ionis to present at upcoming investor conferences PR Newswire
Mar-16-22 07:16PM	Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine PR Newswire
Mar-07-22 07:05AM	Ionis calls for applications for Janice Wiesman Young Investigator Grant Program PR Newswire
Mar-01-22 07:05AM	Ionis to present at the Cowen Annual Health Care Conference PR Newswire
Feb-25-22 10:58AM	Analysts Are More Bearish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Than They Used To Be Simply Wall St.
10:36AM	Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up Zacks
09:46AM	Company News for Feb 25, 2022 Zacks
Feb-24-22 08:15AM	Ionis Pharmaceuticals (IONS) Q4 Earnings and Revenues Beat Estimates Zacks +5.73%
07:00AM	Ionis reports fourth quarter and full year 2021 financial results and recent business achievements PR Newswire
Feb-17-22 03:02PM	Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
10:30AM	2 Unstoppable Growth-Oriented ETFs To Hold for the Long Haul Motley Fool
Feb-10-22 07:05AM	Ionis to hold full year 2021 financial results webcast PR Newswire
Feb-08-22 09:38AM	Grandfield & Dodd, Llc Buys AutoZone Inc, Teledyne Technologies Inc, IAC/InterActiveCorp, ... GuruFocus.com
Feb-07-22 07:30AM	Ionis Pharmaceuticals (NASDAQ:IONS) shareholders have endured a 48% loss from investing in the stock a year ago Simply Wall St.
Feb-01-22 11:43AM	Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis Zacks
Jan-31-22 04:17PM	Pfizer Backs Out Of Deal, But Former Partner Ionis Pares Its Losses Investor's Business Daily
01:18PM	Why Pfizer Stock Is Sliding Today Motley Fool
09:00AM	Why Are Ionis Pharmaceuticals Shares Tanking Today? Benzinga
07:41AM	Ionis, Pfizer scrap plans for experimental cardiovascular drug MarketWatch
07:05AM	Pfizer and Ionis announce discontinuation of vupanorsen clinical development program PR Newswire
Jan-25-22 12:33PM	Ionis' (IONS) Eplontersen Gets Orphan Drug Tag From FDA Zacks
Jan-24-22 01:38PM	Bard Financial Services, Inc. Buys Edison International, Ionis Pharmaceuticals Inc, Omnicom ... GuruFocus.com +5.09%
07:05AM	Ionis announces eplontersen receives orphan drug designation from U.S. FDA PR Newswire
Jan-19-22 01:38PM	Mitchell & Pahl Private Wealth, Llc Buys Fair Isaac Corp, Aspen Technology Inc, Interactive ... GuruFocus.com
07:05AM	Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategy PR Newswire
Jan-18-22 09:07AM	Ionis' (IONS) Partner to Begin New Huntington's Disease Study Zacks -8.95%
12:05AM	Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial PR Newswire
Jan-06-22 05:36AM	The Petri Dish: Janssen inks two local deals, Biogen licenses new drug American City Business Journals
Jan-05-22 11:20AM	Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis Zacks
07:05AM	Ionis to present at 40th Annual J.P. Morgan Healthcare conference PR Newswire
Jan-04-22 07:34AM	Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA GlobeNewswire
07:30AM	Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA PR Newswire
Dec-30-21 10:07AM	AstraZeneca (AZN) Closes Agreement for Eplontersen With Ionis Zacks
Dec-29-21 02:00AM	Ionis and AstraZeneca close deal to develop and commercialize eplontersen PR Newswire
Dec-14-21 11:38PM	VanEck Biotech ETF Buys Icon PLC, Bio-Techne Corp, Natera Inc, Sells , Neurocrine Biosciences ... GuruFocus.com
Dec-11-21 01:05PM	Should I Buy Ionis Pharmaceuticals, Inc. (IONS)? Insider Monkey
Dec-09-21 02:37PM	Omicron Electronics calls latest virus variant an 'unfortunate coincidence' American City Business Journals -5.99%
Dec-08-21 05:37AM	Ionis (IONS) Collaborates With AstraZeneca for Eplontersen Zacks +5.36%
Dec-07-21 02:33PM	Cathie Woods ARK Portfolio: Top 15 Losers Insider Monkey +11.16%
02:00AM	Ionis and AstraZeneca to develop and commercialize eplontersen PR Newswire
Dec-03-21 11:32AM	Ionis Pharmaceuticals (IONS) Down 24.5% Since Last Earnings Report: Can It Rebound? Zacks
Dec-02-21 03:03PM	Ionis to hold virtual investor day event PR Newswire
Nov-24-21 06:30AM	Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen PR Newswire
Nov-18-21 01:30PM	Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema PR Newswire
Nov-12-21 07:05AM	Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021 PR Newswire
Nov-09-21 07:05AM	Ionis to present at upcoming virtual investor conferences PR Newswire
Nov-07-21 07:05AM	Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting PR Newswire
Nov-04-21 08:29AM	Ionis (IONS) Q3 Earnings & Revenues Fall Short of Estimates Zacks
12:01AM	Ionis Pharmaceuticals, inc (IONS) Q3 2021 Earnings Call Transcript Motley Fool
Nov-03-21 08:15AM	Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:00AM	Ionis reports third quarter 2021 financial results and recent business achievements PR Newswire
Nov-02-21 07:05AM	Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia PR Newswire
Oct-27-21 03:03PM	Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-25-21 12:31PM	Hedge Funds Are Betting On Ionis Pharmaceuticals, Inc. (IONS) Insider Monkey
Oct-22-21 10:06AM	Why Ionis Pharmaceuticals Stock Is Down 13% This Week Motley Fool
Oct-20-21 07:05AM	Ionis to hold third quarter 2021 financial results webcast PR Newswire
Oct-18-21 04:07PM	Ionis Stock Collapses On Another 'Misstep' As Biogen-Partnered ALS Drug Flops Investor's Business Daily -13.82%
01:01PM	Biogen Stock Drops as ALS Trial Fails. Ionis Is Getting Hit Even Harder. Barrons.com
Oct-17-21 04:20PM	Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS PR Newswire
06:04AM	3 Stocks to Consider if the October Stock Market Sell-Off Worsens Motley Fool
Oct-14-21 04:06PM	Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting GlobeNewswire
Sep-29-21 06:12AM	3 Biotech Stocks With Huge Catalysts This Fall Motley Fool
Sep-15-21 07:30AM	Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam) GlobeNewswire
Sep-03-21 11:31AM	Ionis Pharmaceuticals (IONS) Up 3% Since Last Earnings Report: Can It Continue? Zacks
07:05AM	Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting PR Newswire
Sep-02-21 07:05AM	Ionis to present at upcoming virtual investor conferences PR Newswire
Aug-09-21 04:11AM	Would Shareholders Who Purchased Ionis Pharmaceuticals' (NASDAQ:IONS) Stock Year Be Happy With The Share price Today? Simply Wall St.
Aug-05-21 10:15AM	Ionis (IONS) Q2 Earnings & Revenues Fall Short of Estimates Zacks
Aug-04-21 06:01PM	Ionis Pharmaceuticals, inc (IONS) Q2 2021 Earnings Call Transcript Motley Fool
08:25AM	Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:00AM	Ionis reports second quarter 2021 financial results and recent business achievements PR Newswire
Aug-02-21 09:30AM	Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events PR Newswire
Jul-29-21 07:05AM	Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen PR Newswire
Jul-28-21 03:04PM	Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-26-21 04:35PM	Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC PR Newswire
Jul-21-21 07:05AM	Ionis to hold second quarter 2021 financial results webcast PR Newswire
Jul-20-21 10:29AM	Hedge Funds Are Selling Ionis Pharmaceuticals, Inc. (IONS) Insider Monkey
Jul-14-21 09:55AM	Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs Zacks
Jul-13-21 08:06AM	Bicycle, Ionis To Develop Targeted Oligonucleotide Therapeutics Benzinga
06:59AM	Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology PR Newswire
Jul-12-21 05:55AM	3 Cathie Wood Stocks You Can Buy for Less Than $50 Motley Fool
Jul-08-21 09:07AM	New Strong Sell Stocks for July 8th Zacks
Jul-06-21 06:30AM	Can These 2 Beaten-Down Biotechs Rebound? Cathie Wood Thinks So. Motley Fool
Jun-19-21 06:02AM	3 Stocks Wall Street Thinks Will Skyrocket 50% or More Motley Fool
Jun-14-21 04:05PM	Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine PR Newswire
Jun-10-21 06:05PM	Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting PR Newswire
07:30AM	New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogens Commitment to Innovation in SMA Therapy GlobeNewswire
Jun-04-21 11:31AM	Why Is Ionis Pharmaceuticals (IONS) Down 7% Since Last Earnings Report? Zacks
Jun-02-21 07:59PM	Ionis announces changes to its board of directors at annual meeting of stockholders PR Newswire

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Swayze Eric	EVP Research	Apr 21	Sale	44.15	378	16,689	20,353	Apr 25 08:56 PM
Cadoret-Manier Onaiza	EVP, Chf Pdt Str & Oper Ofc	Apr 18	Option Exercise	0.00	5,667	0	14,049	Apr 19 08:23 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Apr 12	Sale	40.06	6,792	272,057	34,536	Apr 14 06:02 PM
Monia Brett P	Chief Executive Officer	Apr 01	Sale	37.49	355	13,309	88,662	Apr 05 06:27 PM
PARSHALL B LYNNE	Director	Jan 18	Option Exercise	0.00	5,754	0	79,132	Jan 20 08:21 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 18	Option Exercise	0.00	18,842	0	61,613	Jan 20 08:21 PM
Cadoret-Manier Onaiza	EVP, Chf Corp Dev and Cml Offc	Jan 18	Option Exercise	0.00	6,057	0	10,687	Jan 20 08:21 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 18	Option Exercise	0.00	22,050	0	65,803	Jan 20 08:18 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 18	Option Exercise	0.00	21,086	0	48,094	Jan 20 08:18 PM
Monia Brett P	Chief Executive Officer	Jan 18	Option Exercise	0.00	49,475	0	99,944	Jan 20 08:17 PM
Swayze Eric	EVP Research	Jan 18	Option Exercise	0.00	13,809	0	25,104	Jan 20 08:16 PM
Schneider Eugene	EVP, Chf Clinical Develop Offc	Jan 18	Option Exercise	0.00	10,400	0	17,575	Jan 20 08:16 PM
Geary Richard S	EVP, Chief Development Officer	Jan 18	Option Exercise	0.00	21,391	0	63,357	Jan 20 08:16 PM
Schneider Eugene	EVP, Chf Clinical Develop Offc	Oct 15	Option Exercise	0.00	417	0	7,320	Oct 19 06:29 PM
Hayden Michael R	Director	Oct 15	Option Exercise	0.00	1,777	0	14,222	Oct 19 06:29 PM
Reikes Peter N	Director	Oct 15	Option Exercise	0.00	1,777	0	14,222	Oct 19 06:29 PM
KLEIN JOSEPH III	Director	Jul 15	Option Exercise	0.00	8,666	0	22,460	Jul 19 08:14 PM
BERTHELSEN SPENCER R	Director	Jul 15	Option Exercise	0.00	8,666	0	109,649	Jul 19 08:13 PM
Hayden Michael R	Director	Jul 15	Option Exercise	0.00	7,111	0	12,445	Jul 19 08:13 PM
WENDER JOSEPH H	Director	Jul 15	Option Exercise	0.00	8,666	0	96,971	Jul 19 08:17 PM
PARSHALL B LYNNE	Director	Jul 15	Option Exercise	0.00	8,000	0	73,378	Jul 19 08:16 PM
Reikes Peter N	Director	Jul 15	Option Exercise	0.00	7,111	0	12,445	Jul 19 08:16 PM
LOSCALZO JOSEPH	Chairman of Board	Jul 15	Option Exercise	0.00	8,666	0	25,974	Jul 19 08:14 PM
MUTO FREDERICK T	Director	Jul 15	Option Exercise	0.00	8,666	0	40,349	Jul 19 08:15 PM
HERMAN JOAN E	Director	Jul 15	Option Exercise	0.00	7,111	0	16,000	Jul 19 08:13 PM
KLEIN JOSEPH III	Director	Jul 15	Sale	35.30	4,334	152,989	18,126	Jul 19 08:14 PM
BERTHELSEN SPENCER R	Director	Jun 23	Option Exercise	9.30	15,000	139,500	115,983	Jun 25 05:19 PM
BERTHELSEN SPENCER R	Director	Jun 23	Sale	37.74	15,000	566,100	100,983	Jun 25 05:19 PM
MUTO FREDERICK T	Director	Jun 15	Option Exercise	9.30	15,000	139,500	36,683	Jun 17 05:05 PM
MUTO FREDERICK T	Director	Jun 15	Sale	36.63	15,000	549,500	31,683	Jun 17 05:05 PM
HERMAN JOAN E	Director	Jun 10	Option Exercise	0.00	3,555	0	8,889	Jun 14 06:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience